EUVIMEDEUVIMED entdecken
Crossref

Long-term efficacy and safety of fixed-dose dolutegravir-lamivudine in people with HIV: A retrospective study from India

Vinay Kulkarni iD, Ritu Parchure, Shridevi Gundu, Trupti Darak iD, Kailas Kurkute, Ketan Kulkarni

International Journal of STD & AIDS · 2025

DOI: 10.1177/09564624251352064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of STD & AIDS, 2025. Verfasst von Vinay Kulkarni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Prayas Amrita Clinic, Pune, India. Hauptthemen laut MEDLINE: Pyridones, Heterocyclic Compounds, 3-Ring, HIV Infections, Lamivudine. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

HIV continues to be a significant health concern across the world. Combination antiretroviral therapy (cART) comprising of three-drug regimens has improved clinical outcome but involves long-term toxicity concerns. Hence, to reduce drug exposure, interest in two-drug regimens has increased. This study evaluates the real-world efficacy and safety of a two-drug regimen that is a fixed-dose combination (FDC) of Dolutegravir 50 mg and Lamivudine 300 mg tablets in people living with HIV (PLHIV) in India.

Methods

The retrospective data included PLHIV aged ≥18 years, virally suppressed at baseline, and switched to DTG/3TC between November 2021 and April 2022. Patients were followed for 96 weeks, with routine clinical and laboratory assessments. Virological failure was defined as viral loads >1000 copies/mL, while safety assessments tracked adverse events (AEs), weight gain, and metabolic parameters.

Results

Among 218 patients (mean age 48.08 ± 10.58 yrs), 97.8% achieved virological suppression at 96 weeks with sustained virological suppression at key time points (24, 48, 72, and 96 weeks). CD4 counts improved significantly ( p = .002), specifically in females. Body weight increased moderately, with 16.28% experiencing ≥10% weight gain by 96 weeks. Minor statistically significant variations in cholesterol, triglycerides, and creatinine levels were observed. Nine patients discontinued DTG/3TC due to AEs, primarily weight gain and gastrointestinal issues.

Conclusion

The study demonstrates that the DTG/3TC FDC is an effective, safe, and well-tolerated regimen for maintaining virological suppression in real-world settings, supporting its viable use as a switching strategy in reducing drug exposure and managing long-term toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesHeterocyclic Compounds, 3-RingHIV InfectionsLamivudinePiperazinesOxazinesAnti-HIV AgentsHumansFemaleRetrospective StudiesMaleIndiaMiddle AgedAdultViral LoadCD4 Lymphocyte CountDrug CombinationsTreatment OutcomeSustained Virologic ResponseAntiretroviral Therapy, Highly ActiveDolutegravir

Stichwörter der Autor:innen

CD4DolutegravirHIVlamivudinevirological response

Substanzen

PyridonesHeterocyclic Compounds, 3-RingLamivudinePiperazinesOxazinesAnti-HIV AgentsDrug CombinationsDolutegravir

Autor:innen und Institutionen

  • Prayas Amrita Clinic, Pune, India.
  • Department of Medical Services, Emcure Pharmaceuticals Ltd., Pune, India.

ORCID-Profile: Vinay Kulkarni, Trupti Darak

Zitieren

APA

Kulkarni, V., Parchure, R., Gundu, S., Darak, T., Kurkute, K., & Kulkarni, K. (2025). Long-term efficacy and safety of fixed-dose dolutegravir-lamivudine in people with HIV: A retrospective study from India. International Journal of STD & AIDS. https://doi.org/10.1177/09564624251352064

Vancouver

Kulkarni V, Parchure R, Gundu S, Darak T, Kurkute K, Kulkarni K. Long-term efficacy and safety of fixed-dose dolutegravir-lamivudine in people with HIV: A retrospective study from India. International Journal of STD & AIDS. 2025. doi:10.1177/09564624251352064

BibTeX
@article{Kulkarni2025,
  author = {Kulkarni, Vinay and Parchure, Ritu and Gundu, Shridevi and Darak, Trupti and Kurkute, Kailas and Kulkarni, Ketan},
  title = {Long-term efficacy and safety of fixed-dose dolutegravir-lamivudine in people with HIV: A retrospective study from India},
  journal = {International Journal of STD & AIDS},
  year = {2025},
  doi = {10.1177/09564624251352064}
}
Kostenlos starten →